Four scientist in a laboratory discussing the work

A new frontier
in drug formulation

The Dispersome® technology allows formulation of poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.

Dispersome® - An enabling technology for low solubility drugs


Our Dispersome® platform is based around a class of novel excipients to formulate poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.


By increasing solubility and dissolution rate the Dispersome® platform aims at improving bioavailability, therapeutic outcomes and convenience for patients.


Dispersome® formulations are compatible with standard solid oral dosage form manufacturing processes and facilities.

About Zerion Pharma

Zerion is a pharmaceutical development company improving the formulation of poorly soluble drugs (oral solid dosage forms) that are currently not reaching their therapeutic potential. Through the use of our proprietary formulation platform, Dispersome®, we aim to develop new treatment options for patients across all therapeutic areas.

Learn more

Our technology

Up to 90 % of all new drug molecules are poorly soluble, which can be a problem as the drug must dissolve in order to be absorbed and reach its pharmacological target.

Learn more

Zerion Pharma News

Press Releases
January 10, 2022

New study shows that the amount of active drug in cancer tablets may be reduced by 75% using the Dispersome® technology

January 10, 2022 (COPENHAGEN, Denmark). The Danish drug development company, Zerion Pharma A/S (ZERION) has completed a new animal study (in dogs) that clearly demonstrates the potential of its patented Dispersome®

Press Releases
December 21, 2021

Zerion Pharma elects Dr. Dorte Arnbjerg as a new board member

(Copenhagen, December 21, 2021). ZERION Pharma A/S, a Danish pharmaceutical company, elected Dr. Dorte Arnbjerg to join its board of directors at an extraordinary general meeting held on December 14, 2021. 

Press Releases
November 24, 2021

Zerion Pharma ApS extends its licensing agreement with Rousselot B.V to exploit Dispersome® technology platform

24 November, 2021 (COPENHAGEN, Denmark). Rousselot B.V. and Zerion Pharma ApS announce today that they have strengthened their partnership through an extension of

More news

Zerion Pharma in Press